NEW YORK(GenomeWeb) ­­– The Clinical Proteomic Tumor Analysis Consortium (CPTAC) has contracted researchers to develop targeted mass spec assays for proteins in the RAS signaling pathway as part of an initiative launched by the National Cancer Institute.

Announced last month, the project aims to develop multiple-reaction monitoring mass spec and immuno-MRM mass spec assays for roughly 100 proteins involved in RAS signaling, John Koomen, scientific director of proteomics at Moffitt Cancer Center and one of the participating researchers, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.